NCT03074058View on ClinicalTrials.gov

Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

August 4, 2015

Study Completion Date

August 21, 2015

Conditions
Clinical Pharmacology
Interventions
DRUG

Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)

Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID

DRUG

Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)

Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID

Trial Locations (1)

812-0025

Fukuoka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY